catecholaminergic polymorphic ventricular tachycardia cpvt inherited genetic disorder predisposes affected potentially lifethreatening abnormal heart rhythms arrhythmias arrhythmias seen cpvt typically occur exercise times emotional stress classically take form bidirectional ventricular tachycardia ventricular fibrillation affected may asymptomatic may also experience blackouts even sudden cardiac death cpvt caused genetic mutations affecting proteins regulate concentrations calcium within cardiac muscle cells commonly identified gene encodes protein included ion channel known ryanodine receptor channel releases calcium cells internal calcium store sarcoplasmic reticulum every heartbeat cpvt often diagnosed ecg recorded exercise tolerance test may also diagnosed genetic test condition treated medication including betaadrenoceptor blockers flecainide surgical procedures including sympathetic denervation implantation defibrillator thought affect many one ten thousand people estimated cause unexplained sudden cardiac deaths young people condition first defined underlying genetics described although individuals cpvt may experience symptoms commonly reported symptoms blackouts sudden loss consciousness referred blackouts often occur exercise response emotional chemical messengers known catecholamines adrenaline released within body blackouts may misinterpreted caused simple faints epilepsy often leading delays reaching correct third affected first manifestation disease may cardiac arrest potentially leading sudden occur young children presenting sudden infant death syndrome cot approximately cpvt family member experienced blackouts seizures sudden death response exercise cpvt catecholamine release lead abnormal heart rhythm arrhythmia known ventricular ventricular tachycardia may take characteristic form known bidirectional ventricular tachycardia form ventricular tachycardia occurs relatively infrequently seen suggestive underlying diagnosis cpvt related condition andersentawil ventricular arrhythmias cases terminate causing blackout person recovers however abnormal heart rhythm continues degenerate dangerous arrhythmia known ventricular fibrillation causing cardiac arrest untreated sudden typically abnormal signs clinical examination persons cpvt however cpvt may develop less serious heart rhythm disturbance called atrial fibrillation detected examination irregular furthermore approximately cpvt slow resting heart rate known sinus arrhythmias cpvt experience caused abnormalities way cardiac muscle cells control levels calcium interacts protein fibres myofibrils inside cell allow cell contract concentration calcium within cell needs tightly regulated heartbeat concentration calcium must rise allow muscle contract fall allow muscle relax process achieved using store within cell known sarcoplasmic start heartbeat calcium released sarcoplasmic reticulum specialised channels known ryanodine ryanodine receptors open concentration calcium near channel increases happens response electrical signal cell membrane called action potential small amount calcium flows across cell membrane cell ltype calcium channels many located specialised inpouchings membrane called ttubules designed bring surface ion channels close sarcoplasmic increase calcium concentration triggers ryanodine receptors sarcoplasmic reticulum release puff calcium known calcium spark spark triggers release sparks neighbouring ryanodine receptors create organised rise calcium throughout cell known calcium transient end heartbeat calcium pumped back protein called serca along regulatory protein phospholamban calcium held within sarcoplasmic reticulum protein called finetuning process achieved phosphorylating proteins example exercise catecholamines activate betaadrenoceptors cell surface trigger protein kinase phosphorylate ltype calcium channel increasing flow calcium cell simultaneously phosphorylation regulatory protein phospholamban causes calcium drawn sarcoplasmic reticulum overall effect generate larger calcium transient beat leading forceful alterations proteins involved excitationcontraction coupling disrupt carefully regulated process cpvt normally tight regulation calcium become deranged leading calcium generally released sarcoplasmic reticulum response action potential calcium sparks also occur spontaneously healthy heart spontaneous calcium spark generally isolated event goes ryanodine receptors proteins regulate abnormal sparks trigger releases neighbouring ryanodine receptors spread throughout cell calcium calcium waves much likely occur cardiac muscle cells stimulated catecholamines adrenaline increase concentration calcium within sarcoplasmic reticulum sensitise ryanodine uncontrolled wave calcium forced cell membrane via sodiumcalcium exchanger causing electric current known delayed afterdepolarisation afterdepolarisations large enough trigger additional action potentials premature ventricular contractions sustained cpvt caused mutations several genes responsible regulating concentrations calcium within cardiac muscle cells commonly identified genetic mutation cpvt mutation gene encodes cardiac ryanodine receptor responsible releasing calcium sarcoplasmic mutations associated cpvt also identified gene encodes protein binds calcium within sarcoplasmic reticulum genes associated rarer atypical forms include tecrl encoding reductaselike protein encoding calmodulin trdn encoding commonly identified genetic mutations cpvt occur gene encodes cardiac ryanodine mutations gene lead autosomal dominant form typical cpvt known precise effect differs specific mutations gene many mutations cause ryanodine receptor open response lower concentrations threshold calcium release result sarcoplasmic reticulum spontaneously releases calcium abnormal ryanodine receptors concentration calcium within sarcoplasmic reticulum rises process known storeoverload induced calcium sarcoplasmic reticulum calcium content increases response stimulation catecholamines explaining arrhythmias cpvt occur times catecholamine levels elevated suggest increased sensitivity calcium occurs ryanodine receptor phosphorylated protein kinase suggest increased sensitivity also occurs resting two theories proposed underlying mechanism mutations promote storeoverload induced calcium release domain unzipping domain unzipping refers separation two important regions ryanodine receptor nterminus central domain mechanism mutation might destabilise ryanodine receptors closed state increase sensitivity second potential mechanism involves regulatory protein protein binds stabilises ryanodine receptor binding ryanodine receptor regulated phosphorylation phosphorylation protein kinase leads dissociation rendering ryanodine receptor sensitive cytosolic calcium mutations may interfere binding ryanodine receptor thereby increase sensitivity calcium likely plays role cpvt mutations mutations responsible cpvt mainly found four major domains mutations affecting domains iii iv gene corresponding nterminal region protein cytosolic linker respectively occur cases mutations seen less frequently affecting domains ii encode sections nterminal region mutations associated cpvt occur outside four domains rare responsible reported cases mutations often missense mutations single nucleotide substitutions causing one amino acid replaced another although inframe substitutions duplications described damaging nonsense mutations reported association cpvt potentially variants may lead different cardiac diseases mutations gene associated autosomal recessive form typical cpvt known gene encodes calsequestrin major calciumbinding protein calcium buffer within sarcoplasmic mutations account cases fourteen mutations identified association cpvt two nonsense mutations causing protein abnormally short two deletion mutations ten missense mutations substitute one amino acid another chain forming mutations cause decrease sarcoplasmic reticulum calciumbuffering capacity means abrupt changes sarcoplasmic total calcium buffered less therefore translate larger shifts free calcium higher peaks free calcium greater potential cause storeoverload induced calcium release sarcoplasmic reticulum leading addition role calcium buffer calsequestrin also regulates release calcium sarcoplasmic reticulum directly modulating ryanodine receptors concentration calcium low calsequestrin monomers form complex proteins triadin junctin inhibit ryanodine however high calcium concentrations calsequestrin forms polymers dissociate ryanodine receptor channel complex removing inhibitory response increasing sensitivity ryanodine receptor spontaneously releasing decreased also associated high levels calreticulin protein among roles regulates reuptake calcium sarcoplasmic reticulum absence calreticulin levels increase provide compensatory calcium binding within sarcoplasmic reticulum possible calreticulin may contribute generation arrhythmias seen association cpvt may challenging diagnose structure heart appears normal affected condition assessed using echocardiogram cardiac mri scan cardiac ct scan electrical function heart also appears normal rest assessed using standard however response exercise catecholamines adrenaline abnormal heart rhythms bidirectional ventricular tachycardia frequent polymorphic ventricular ectopic beats may resting ecg useful test differentiate cpvt electrical diseases heart cause similar abnormal heart rhythms unlike conditions long qt syndrome brugada syndrome resting ecg cpvt generally however approximately affected slow resting heart rate sinus exercise testing commonly performed treadmill stationary bicycle help diagnose cpvt test cpvt often experience ectopic beats may progress bidirectional polymorphic ventricular tachycardia intensity exercise suspected cpvt young children may able perform exercise tolerance test cases alternative forms testing include adrenaline provocation testing adrenaline infused vein gradually increasing doses close supervision ecg additionally long term holter ecg monitoring performed although form testing less likely detect arrhythmia invasive electrophysiological studies provide useful information help diagnose cpvt assess risk lifethreatening cpvt also diagnosed identifying diseasecausing mutation gene associated cpvt using genetic technique may way identify condition someone suspected cpvt died case may known molecular treatments cpvt aim prevent lethal abnormal heart rhythms occurring rapidly restore normal rhythm occur arrhythmias cpvt generally occur times heart exposed high levels adrenaline similar chemical messengers catecholamines many treatments cpvt aim lower levels catecholamines heart exposed block effects firstline treatment cpvt involves lifestyle advice includes avoiding competitive sports strenuous exercise highly stressful environments high levels adrenaline occur settings provoke several medications useful cpvt mainstays treatment beta blockers block effects adrenaline catecholamines heart reducing chance abnormal heart rhythms beta blockers nadolol proven effective treating drug lowers heart rate greater extent beta blockers needs taken daily reducing risk missed doses nadolol may difficult obtain available countries alternative beta blocker suitable use cpvt may propranolol however complex dosing recently published data suggest use selective beta blockers atenolol bisoprolol metoprolol associated high treatment failure flecainide class antiarrhythmic drug recommended cpvt experience abnormal heart rhythms despite taking beta flecainide reduces risk arrhythmias cpvt remains uncertain flecainide achieves suggested flecainide directly interacts cardiac ryanodine receptor frequently abnormal cpvt suggest antiarrhythmic effects flecainide rely entirely sodium channel blocking verapamil calcium channel antagonist combined beta blocker may reduce risk arrhythmias patients propafenone another antiarrhythmic may reduce risk arrhythmias potentially direct effects ryanodine persons cpvt continue experience lifethreatening arrhythmias despite pharmaceutical therapy case surgical procedure used affect nerves supplying heart communicate using collection nerves known sympathetic nervous system supply heart well organs nerves activated encourage heart beat harder sympathetic nervous system uses noradrenaline catecholamine chemical messenger neurotransmitter promote arrhythmias prevent region sympathetic nervous system intentionally damaged operation known cardiac sympathetic denervation sympathetic nervous system feeds heart sides often left sided nerves targeted sympathectomy although destruction nerves sides may process sympathectomy effective decreasing abolishing risk lifethreatening medication sympathectomy aim prevent abnormal heart rhythms occurring first place implantable defibrillator icd may used treat arrhythmias medication failed prevent restore normal heart devices usually implanted skin front chest shoulder continuously monitor heart abnormal heart rhythms lifethreatening arrhythmia detected device deliver small electric shock terminate abnormal rhythm restart implantable defibrillators often recommended cpvt experienced blackouts ventricular arrhythmias cardiac arrest despite taking appropriate devices lifesaving shown use confers significant survival benefit patients suggested resulting surge adrenaline caused pain electric shock device could theoretically bring cycle recurrent arrhythmias shocks known electrical therefore strongly recommended icd implanted cpvt take beta blocker dampen effects significant proportion cpvt experience lifethreatening abnormal heart rhythm estimates risk ranging course lifethreatening arrhythmias likely occur cpvt diagnosed childhood person cpvt take beta blockers arrhythmias occur exercise testing despite taking beta treatment nadolol preferred beta blocker treatment cpvt event rates estimated per year patients treated beta blockers lifethreatening arrhythmias likely person already survived cardiac arrest syncope carriers diseasecausing mutations affecting highly conserved terminal portion called cterminal domain amino acids cpvt estimated affect symptoms cpvt typically first seen first second decade affected individuals experience first episode syncope cardiac arrest age syncope exercise strong emotion considered red characteristic disease lastly small number patients may present later life genetic testing patients frequently fails identify causative norwegian cardiologist knut berg published report three sisters blackouts exercise emotional stress recognised first description bidirectional ventricular tachycardia associated condition described term catecholaminergic polymorphic ventricular tachycardia first used first genetic mutation causing cpvt identified localised chromosome found variant gene ongoing research aims identify better treatments cpvt increase understanding mechanisms arrhythmia identify genes causing httpsenwikipediaorgwikicatecholaminergicpolymorphicventriculartachycardia